Other equities analysts have also issued research reports about the stock. ValuEngine lowered shares of Cytokinetics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, December 20th. HC Wainwright reissued a “buy” rating and issued a $21.00 price objective on shares of Cytokinetics in a research report on Tuesday, January 22nd. Zacks Investment Research raised shares of Cytokinetics from a “hold” rating to a “buy” rating and set a $7.75 price objective for the company in a research report on Monday, January 21st. Finally, Piper Jaffray Companies boosted their price objective on shares of Cytokinetics from $12.00 to $13.00 and gave the company an “overweight” rating in a research report on Wednesday, March 20th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Cytokinetics currently has a consensus rating of “Buy” and an average price target of $13.15.
Shares of CYTK opened at $8.08 on Thursday. The company has a quick ratio of 9.36, a current ratio of 9.36 and a debt-to-equity ratio of 1.53. The stock has a market cap of $447.41 million, a price-to-earnings ratio of -4.14 and a beta of 2.07. Cytokinetics has a 12-month low of $5.75 and a 12-month high of $10.44.
Cytokinetics (NASDAQ:CYTK) last announced its earnings results on Thursday, February 21st. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.03. The company had revenue of $9.38 million during the quarter, compared to analysts’ expectations of $3.46 million. Cytokinetics had a negative net margin of 337.42% and a negative return on equity of 168.21%. As a group, research analysts anticipate that Cytokinetics will post -1.75 earnings per share for the current year.
Several large investors have recently bought and sold shares of CYTK. Great Point Partners LLC raised its position in shares of Cytokinetics by 45.6% in the fourth quarter. Great Point Partners LLC now owns 3,173,288 shares of the biopharmaceutical company’s stock valued at $20,055,000 after buying an additional 993,600 shares during the last quarter. BlackRock Inc. grew its holdings in Cytokinetics by 9.5% in the third quarter. BlackRock Inc. now owns 8,698,387 shares of the biopharmaceutical company’s stock valued at $85,680,000 after purchasing an additional 754,593 shares during the period. Fosun International Ltd purchased a new stake in Cytokinetics in the fourth quarter valued at approximately $1,113,000. Foresite Capital Management IV LLC purchased a new stake in Cytokinetics in the fourth quarter valued at approximately $1,107,000. Finally, Dimensional Fund Advisors LP grew its holdings in Cytokinetics by 233.6% in the third quarter. Dimensional Fund Advisors LP now owns 229,377 shares of the biopharmaceutical company’s stock valued at $2,259,000 after purchasing an additional 160,622 shares during the period. 71.79% of the stock is owned by institutional investors and hedge funds.
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.